9:30 Registration and welcome coffee
10:00 Welcome from hosts
10:10 Session 1
11:40 Lunch & Networking
12:10 Session 2
13:40 Pre-arranged meetings (Coffee and Networking for anyone wanting to stay)
15:00 Closing
Free registration opened to all NLSDays participants.
Registration and partnering website opening soon.
Welcome and introduction to the workshop and brief intro EUSME
Eurostars in FR. Funding and support to applicants. FR-SE Bilateral Call
Questions from the audience
This year we inaugurate the new Nordic Life Science Awards completion, opened to two participants categories, academia and early stage companies.
Part 1 – Academia
“Advancing academic ideas into innovations for patients”
Academia is a key engine for medical innovation and many life science projects becoming commercial successful originate from academic centers. Big ideas very often come from ground-braking academic research. Recognizing that the majority of the global companies made academic-industrial partnerships an integral part of their strategies and opened their R&D organizations to external innovation.
The Nordic Life Science Award for Academia features exciting academic projects from five Nordic countries illustrating the rich and broad research milieus and their motivations to advance their ideas into innovations for patients. The session is hosted by SPARK Norway and delivered in collaboration with SPARK Finland, SciLifeLab Sweden and the Danish BioInnovation Institute.
The opening plenary welcomes you all and marks the beginning of the 7thNordic Life Science Days! Get inspired and listen to our highly ambitions Nordic life science agenda.
Moderator(s): Ms. Helena Strigård - Deputy Director General, SwedenBIO
Speaker(s):
Mr. Olivier Duchamp - Managing Director, NLSDays - VP International BD & Promotion, SwedenBIO
Ms. Ann Linde - Swedish Minister for Foreign Trade, with responsibility for Nordic affairs
Mr. Hans Erik Henriksen - CEO, HealthCare Denmark
Measured by the high level of business activities and the impressive number of companies, the Nordic life science sector is strong in an international context and has contributed to many innovations on the global market. Appropriate and timely financing is a must for the Nordic life science companies in order to progress the development of their respective project pipelines. This session highlights specific Nordic features such as the growing number of early to mid-stage companies listed at the stock exchanges and discuss how to maintain a sustainable life science capital market in the Nordics.
Part 1: From seed to IPO “pitch”
Part 2: Stockholm, the capital of IPOs (IPOs as exit possibility for VCs)
Part 3: Maintaining a sustainable life science capital market in the Nordics
Moderator(s): Dr. Sonja Benhamida - Senior Vice President Healthcare, DNB
Speaker(s):
Mr. Stephan Christgau - Senior Partner, Novo Seeds
Mr. Andreas Lindblom - CEO, Sciety
Mr. Ari-Pekka Laitsaari - Growth Capital and Innovation Finance, European Investment Bank
Mr. Shutian Liu - Managing Partner and Founding Partner, Button Capital
Mr. Adam Kostyal - Senior Vice President, Nasdaq OMX
Mr. Fredrik Konopik - Head of Equity Capital Markets, DNB Markets
10:45 Ferring Pharmaceuticals - Pharmaceutical 11:00 Johnson & Johnson Innovation - Pharmaceutical 11:15 MSD - Pharmaceutical 11:30 Pfizer - Pharmaceutical 11:45 Sanofi - Pharmaceutical 12:00 Amgen - Pharmaceutical
Neuroscience has not only proven to be one of the most challenges areas for finding treatments, it is also one of the diseases putting the greatest burden on society. Current treatment will only temporarily improve symptoms but are there new treatments around the corner potentially stopping or significantly delaying the progression of the disease? International experts will share their views on what is possible based on the knowledge currently available.
Moderator(s): Ms. Ingrid Heath - Partner, Adlersson & Heath
Speaker(s):
Dr. Jina Elise Swartz - Global Clinical Development, MSD
Dr. Per-Ola Freskgård - CSO, BioArctic
Dr. Steffen Thirstrup - Director, NDA Regulatory Advisory Board
Dr. Göran Gustafsson - Department Head, Printed Electronics, Biocom Lab/RISE
Dr. Patrick Sobocki - Investment Manager, Industrifonden
14:00 Annexin Pharmaceuticals - Biotechnology - Therapeutics & Diagnostics 14:13 Aqilion - Biotechnology - Therapeutics & Diagnostics 14:26 Beactica - Pharmaceutical 14:39 CanImGuide Therapeutics - Biotechnology - Therapeutics & Diagnostics 14:52 Gedea Biotech - Biotechnology - Therapeutics & Diagnostics 15:05 Immunicum - Biotechnology - Therapeutics & Diagnostics 15:18 DelSiTech - Pharmaceutical 15:31 Scandinavian Biopharma - Biotechnology - R&D Services
Moderator(s): Mr. Sverre Bengtsson - Co-Founder, Owner and Sr VP Strategic Relations, Pharma Consulting Group
Speaker(s):
Dr. John Montana - Corporate VP, Integrated Drug Discovery & Strategic Projects, Charles River Laboratories
Dr. Peter Gaskin - Senior Director, Scientific Advisory Services, Charles River Laboratories
Dr. Eric Meldrum - CSO, ENYO Pharma
Moderator(s): Dr. Christina Östberg Lloyd - Clinical Medical Regulatory Director, Novo Nordisk & Chairman, SWELife
Speaker(s):
Prof. Malin Parmar - Associate Professor, Lund University
Dr. Mathias Svahn - CEO, NextCell Pharma
Dr. Carlos de Sousa - CEO, Immunicum
Dr. Christoph Varenhorst - Medical Director, Pfizer
Dr. Peter Hovstadius - Chief Scientific Officer Nordics, Novartis
15:45 EY - Professional Services & Consulting 16:01 EIT Health Scandinavia - Public & Non-Profit Organizations 16:14 S-cubed - CRO/CMO/CDMO 16:21 S-cubed - CRO/CMO/CDMO 16:28 Venn Life Sciences - CRO/CMO/CDMO 16:35 GEA - Supplier & Engineering
Welcome to an interactive session on Innovative Medicines Initiative (IMI), an EU public-private partnership funding health research and innovation. This is the opportunity for you as an SME, patient organisation, healthcare industry or academia representative or any other key healthcare player, to learn more about how to engage with IMI, upcoming calls, get a SME testimonial and – most of all- a chance to get your questions answered !
Moderator(s): Ms. Caroline Ekstrand - Program Manager, Vinnova
Speaker(s):
Mr. Nicolas Creff - Senior Manager, Research Partnerships and Science Policy and Regulatory Affairs, EFPIA
Ms. Magali Poinot - Advisor to Executive Director, IMI Executive Office
Dr. Karin von Wachenfeldt - CEO, Truly Labs
Dr. Gunnar Sandberg - Chair of IMI State Representative Group and Program Manager, Vinnova
Dr. Elisabet Nielsen - Program Manager, Vinnova
Moderator(s): Ms. Louise Jonshammar - Attorney At Law, AWA
Speaker(s):
Dr. Niclas Nilsson - Head of Open Innovation in Research, Leo Pharma
Dr. Magnus Larsson - Vice President, Head of Unit Surface - Process and Formulation, RISE
Dr. Michael L. Salgaller - Supervisor, Invention Development and Marketing Unit (IDMU), National Institutes of Health
17:15 Charles River - CRO/CMO/CDMO 17:31 Cobra Biologics - CRO/CMO/CDMO 17:44 Recipharm - CRO/CMO/CDMO 17:57 Coriolis Pharma - CRO/CMO/CDMO 18:10 Mercodia - Supplier & Engineering
An outstanding location overlooking the Øresund bridge combining the raw nature in the best way with a futuristic expression in architecture.
Shuttle busses will depart from MalmöMässan main entrance from 18:30 until 19:30
Shuttle busses will depart from Luftkastellet from 21:30 until 22:30 to Malmömässan and main hotels downtown Malmö.
Moderator(s): Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group
Speaker(s):
Dr. Michel de Baar - Executive Director, BD&L - Infectious Diseases, Vaccines, Cardiometabolic, Immunology & Inflammation, MSD
Mr. Thomas Magnusson - Chairman of the Board, DIOS (Diabetesorganisationen I Sverige)
Dr. Damon Tojjar - Managing Director, Easy Diabetes
08:45 Sirion Biotech - Biotechnology - Other 08:52 Vicore Pharma - Biotechnology - R&D Services 09:05 ENYO Pharma - Biotechnology - Therapeutics & Diagnostics 09:18 AstraZeneca - Pharmaceutical 09:34 Bristol-Myers Squibb - Pharmaceutical 09:50 Boehringer Ingelheim - Pharmaceutical
Moderator(s): Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group
Speaker(s):
Dr. Mark Swindells - Chief Operating Officer, Exscientia
Ms. Kaisa Helminen - CEO, Aiforia Technologies
Dr. Jørn Skibsted Jakobsen - Vice President, Global Clinical Research and Development, Ferring Pharmaceuticals
Prof. Carl Borrebaeck - Professor, Lund University
Dr. George Coukos - Director Department of Oncology, University of Lausanne
10:45 Cartana - Biotechnology - R&D Services 10:52 Abera Bioscience - Biotechnology - Therapeutics & Diagnostics 10:59 Index Pharmaceuticals - Pharmaceutical 11:06 NextCell Pharma - Biotechnology - Therapeutics & Diagnostics 11:13 Sigrid Therapeutics - Biotechnology - Therapeutics & Diagnostics 11:20 Sinfonia Biotherapeutics - Biotechnology - Therapeutics & Diagnostics 11:27 HepaPredict - CRO/CMO/CDMO 11:34 Ilya Pharma - Pharmaceutical 11:41 Research Institutes of Sweden - Public & Non-Profit Organization 11:48 Research Institutes of Sweden - Public & Non-Profit Organization 11:55 S-cubed - CRO/CMO/CDMO 12:02 Immuneed - CRO/CMO/CDMO 12:09 LGC Group - CRO/CMO/CDMO 12:16 Particle Analytical - CRO/CMO/CDMO
Moderator(s): Dr. Ulrica Sehlstedt - Management Consultant, Arthur D. Little
Speaker(s):
Dr. Magnus R. Björsne - CEO, AZ BioVentureHub
Dr. Anders Holmén - VP and Head of Pharmaceutical Sciences, BioPharmceuticals R&D, AstraZeneca
MAX IV and ESS, DESY and European XFEL position Northern Europe as a globally unique region for Life Science Innovation and Research. Get inspiration on how to develop your products and stay competitive within your area. The session will include an interactive panel discussion and take off from the newly started EU project ‘Hanseatic League of Science (HALOS)’, www.halos.lu.se
Speaker(s):
Prof. Erik Renström - Professor, Lund University
Assoc. Prof. Kajsa Paulsson - Associate Professor, Lund University
Dr. Selma Maric - Coordinator Industrial Relation, Life Sciences, MAX IV
Assoc. Prof. Tomas Lundqvist - Coordinator for Large Scale Research Infrastructures, RISE
Dr. Anna Sandström - Science Policy and Relations Director Europe, AstraZeneca
Dr. Anna Stenstam - CEO, CR Competence